KR102341064B1 - 리소포스파티드산 수용체 1 (lpar1) 억제제 화합물 - Google Patents
리소포스파티드산 수용체 1 (lpar1) 억제제 화합물 Download PDFInfo
- Publication number
- KR102341064B1 KR102341064B1 KR1020207006096A KR20207006096A KR102341064B1 KR 102341064 B1 KR102341064 B1 KR 102341064B1 KR 1020207006096 A KR1020207006096 A KR 1020207006096A KR 20207006096 A KR20207006096 A KR 20207006096A KR 102341064 B1 KR102341064 B1 KR 102341064B1
- Authority
- KR
- South Korea
- Prior art keywords
- methyl
- phenyl
- pyrazol
- amino
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- JQXBZEQRXQPLOC-UHFFFAOYSA-N CC(C)Oc1nc(Cl)cnc1 Chemical compound CC(C)Oc1nc(Cl)cnc1 JQXBZEQRXQPLOC-UHFFFAOYSA-N 0.000 description 2
- MTEXKCUMSUVVFX-UHFFFAOYSA-N CC(C)(C(C)(C)O[B+]c1c(C)cc(C2(CC2)C#N)cc1)O Chemical compound CC(C)(C(C)(C)O[B+]c1c(C)cc(C2(CC2)C#N)cc1)O MTEXKCUMSUVVFX-UHFFFAOYSA-N 0.000 description 1
- XAKNTOZVGAZPRK-UHFFFAOYSA-N CC(C)(c1cncc(Nc([n](C)nc2)c2-c(nc2)ccc2-c2ccc(C3(CC3)C(O)=O)cc2)n1)OC Chemical compound CC(C)(c1cncc(Nc([n](C)nc2)c2-c(nc2)ccc2-c2ccc(C3(CC3)C(O)=O)cc2)n1)OC XAKNTOZVGAZPRK-UHFFFAOYSA-N 0.000 description 1
- VDRYFAODWTWROB-UHFFFAOYSA-N CC(C)Oc1cncc(Nc([n](C)nc2)c2-c(cc2)ncc2Br)n1 Chemical compound CC(C)Oc1cncc(Nc([n](C)nc2)c2-c(cc2)ncc2Br)n1 VDRYFAODWTWROB-UHFFFAOYSA-N 0.000 description 1
- ZZSFPTQQTDFPRH-UHFFFAOYSA-N CC(C)c1cncc(Cl)n1 Chemical compound CC(C)c1cncc(Cl)n1 ZZSFPTQQTDFPRH-UHFFFAOYSA-N 0.000 description 1
- 0 CC(C)c1cncc(Nc([n](C)nc2)c2-c(cc2)ncc2-c2cnc(C3(CC3)C(*)=O)cc2)n1 Chemical compound CC(C)c1cncc(Nc([n](C)nc2)c2-c(cc2)ncc2-c2cnc(C3(CC3)C(*)=O)cc2)n1 0.000 description 1
- PVHOYFDBKKNFBQ-UHFFFAOYSA-N CC1(C)OB(c(cc2)ccc2-c2ccc(C3(CC3)C(OC)=O)cc2)OC1(C)C Chemical compound CC1(C)OB(c(cc2)ccc2-c2ccc(C3(CC3)C(OC)=O)cc2)OC1(C)C PVHOYFDBKKNFBQ-UHFFFAOYSA-N 0.000 description 1
- LRDNEAQDPIFKFF-VOTSOKGWSA-N CCO/C=C(/c(ncc(Cl)c1)c1F)\C#N Chemical compound CCO/C=C(/c(ncc(Cl)c1)c1F)\C#N LRDNEAQDPIFKFF-VOTSOKGWSA-N 0.000 description 1
- UMLXPHDZTYNYFK-UHFFFAOYSA-N CCOC(C1(CC1)c(cc1C)ccc1Br)=O Chemical compound CCOC(C1(CC1)c(cc1C)ccc1Br)=O UMLXPHDZTYNYFK-UHFFFAOYSA-N 0.000 description 1
- OIPNJMFDZMBDQB-UHFFFAOYSA-N COCc(cc(C1(CC1)C(OC)=O)cc1)c1Br Chemical compound COCc(cc(C1(CC1)C(OC)=O)cc1)c1Br OIPNJMFDZMBDQB-UHFFFAOYSA-N 0.000 description 1
- KZLCUPIDUSJENX-UHFFFAOYSA-N C[n]1ncc(-c(cc2)ncc2-c2ccc(C3(CC3)C(O)O)cc2)c1Nc1nc(Cl)cnc1 Chemical compound C[n]1ncc(-c(cc2)ncc2-c2ccc(C3(CC3)C(O)O)cc2)c1Nc1nc(Cl)cnc1 KZLCUPIDUSJENX-UHFFFAOYSA-N 0.000 description 1
- FGMXQSJPBQOKON-UHFFFAOYSA-N C[n]1ncc(-c(cc2)ncc2-c2ccc(C3(CC3)C(OC)=O)cc2)c1Nc1nc(OC2CCC2)cnc1 Chemical compound C[n]1ncc(-c(cc2)ncc2-c2ccc(C3(CC3)C(OC)=O)cc2)c1Nc1nc(OC2CCC2)cnc1 FGMXQSJPBQOKON-UHFFFAOYSA-N 0.000 description 1
- CLFRHFGBMPJLSM-UHFFFAOYSA-N C[n]1ncc(-c(cc2)ncc2-c2ncc(C3(CC3)C#N)cc2)c1N Chemical compound C[n]1ncc(-c(cc2)ncc2-c2ncc(C3(CC3)C#N)cc2)c1N CLFRHFGBMPJLSM-UHFFFAOYSA-N 0.000 description 1
- HUZVQWPMCLLZLR-UHFFFAOYSA-N C[n]1ncc(-c(cc2)ncc2Br)c1N Chemical compound C[n]1ncc(-c(cc2)ncc2Br)c1N HUZVQWPMCLLZLR-UHFFFAOYSA-N 0.000 description 1
- CKUVSPQGYLELRG-UHFFFAOYSA-N Cc1nc(Cl)cnc1 Chemical compound Cc1nc(Cl)cnc1 CKUVSPQGYLELRG-UHFFFAOYSA-N 0.000 description 1
- LSEAAPGIZCDEEH-UHFFFAOYSA-N Clc1nc(Cl)cnc1 Chemical compound Clc1nc(Cl)cnc1 LSEAAPGIZCDEEH-UHFFFAOYSA-N 0.000 description 1
- LUCZNZCHVZCMLQ-UHFFFAOYSA-N Clc1nc(OC2CCC2)cnc1 Chemical compound Clc1nc(OC2CCC2)cnc1 LUCZNZCHVZCMLQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2017/100354 | 2017-09-04 | ||
| PCT/CN2017/100354 WO2019041340A1 (en) | 2017-09-04 | 2017-09-04 | LYSOPHOSPHATIDE ACID RECEPTOR 1 RECEPTOR INHIBITORS (LPAR1) |
| PCT/US2018/048249 WO2019046239A1 (en) | 2017-09-04 | 2018-08-28 | LYSOPHOSPHATIDE ACID RECEPTOR 1 RECEPTOR INHIBITORS (LPAR1) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20200035440A KR20200035440A (ko) | 2020-04-03 |
| KR102341064B1 true KR102341064B1 (ko) | 2021-12-20 |
Family
ID=63528947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207006096A Active KR102341064B1 (ko) | 2017-09-04 | 2018-08-28 | 리소포스파티드산 수용체 1 (lpar1) 억제제 화합물 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11365185B2 (https=) |
| EP (1) | EP3679032B1 (https=) |
| JP (1) | JP6854386B2 (https=) |
| KR (1) | KR102341064B1 (https=) |
| CN (1) | CN111032647B (https=) |
| AU (1) | AU2018323969B2 (https=) |
| CA (1) | CA3073983C (https=) |
| EA (1) | EA039482B1 (https=) |
| ES (1) | ES2966827T3 (https=) |
| IL (1) | IL273000B2 (https=) |
| MX (1) | MX2020002430A (https=) |
| SA (1) | SA520411406B1 (https=) |
| WO (2) | WO2019041340A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020384883B2 (en) | 2019-11-15 | 2023-11-16 | Gilead Sciences, Inc. | Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof |
| TWI843503B (zh) | 2020-06-03 | 2024-05-21 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| CN115867556B (zh) | 2020-06-03 | 2025-05-06 | 吉利德科学公司 | Lpa受体拮抗剂及其用途 |
| TWI853704B (zh) | 2021-05-11 | 2024-08-21 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| KR20240007233A (ko) | 2021-05-13 | 2024-01-16 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제 및 이의 용도 |
| CN113461640B (zh) * | 2021-06-17 | 2023-08-11 | 中央民族大学 | Lpar1抑制剂、医药用途及其制备方法 |
| WO2023107938A1 (en) | 2021-12-08 | 2023-06-15 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| AR128613A1 (es) | 2022-02-25 | 2024-05-29 | Lhotse Bio Inc | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa |
| WO2024112895A1 (en) * | 2022-11-24 | 2024-05-30 | Lhotse Bio, Inc. | Compounds and compositions for treating conditions associated with lpa receptor activity |
| KR20260019497A (ko) * | 2023-06-02 | 2026-02-10 | 주식회사 메타이뮨 | 섬유성 질환 치료용 화합물 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012138648A1 (en) | 2011-04-06 | 2012-10-11 | Irm Llc | Compositions and methods for modulating lpa receptors |
| US20130253004A1 (en) | 2010-12-07 | 2013-09-26 | Amira Pharmaceuticals, Inc. | Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2466121B (en) * | 2008-12-15 | 2010-12-08 | Amira Pharmaceuticals Inc | Antagonists of lysophosphatidic acid receptors |
| GB2474120B (en) * | 2009-10-01 | 2011-12-21 | Amira Pharmaceuticals Inc | Compounds as Lysophosphatidic acid receptor antagonists |
| GB2474748B (en) * | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
| CN103596947A (zh) * | 2011-04-05 | 2014-02-19 | 艾米拉医药股份有限公司 | 用于治疗纤维化、疼痛、癌症和呼吸、过敏性、神经系统疾病或心血管疾病的基于3-或5-联苯-4-基异噁唑的化合物 |
| US9526091B2 (en) * | 2012-03-16 | 2016-12-20 | Intel Corporation | Method and apparatus for coordination of self-optimization functions in a wireless network |
| KR20180082564A (ko) * | 2015-11-20 | 2018-07-18 | 우베 고산 가부시키가이샤 | Nash의 치료 또는 예방을 위한 의약 조성물 |
-
2017
- 2017-09-04 WO PCT/CN2017/100354 patent/WO2019041340A1/en not_active Ceased
-
2018
- 2018-08-28 US US16/633,371 patent/US11365185B2/en active Active
- 2018-08-28 MX MX2020002430A patent/MX2020002430A/es unknown
- 2018-08-28 CN CN201880053540.2A patent/CN111032647B/zh active Active
- 2018-08-28 WO PCT/US2018/048249 patent/WO2019046239A1/en not_active Ceased
- 2018-08-28 AU AU2018323969A patent/AU2018323969B2/en active Active
- 2018-08-28 EA EA202090368A patent/EA039482B1/ru unknown
- 2018-08-28 EP EP18766481.8A patent/EP3679032B1/en active Active
- 2018-08-28 ES ES18766481T patent/ES2966827T3/es active Active
- 2018-08-28 KR KR1020207006096A patent/KR102341064B1/ko active Active
- 2018-08-28 JP JP2020512678A patent/JP6854386B2/ja active Active
- 2018-08-28 CA CA3073983A patent/CA3073983C/en active Active
-
2020
- 2020-02-25 SA SA520411406A patent/SA520411406B1/ar unknown
- 2020-03-01 IL IL273000A patent/IL273000B2/en unknown
-
2022
- 2022-05-18 US US17/747,261 patent/US12145924B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130253004A1 (en) | 2010-12-07 | 2013-09-26 | Amira Pharmaceuticals, Inc. | Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis |
| WO2012138648A1 (en) | 2011-04-06 | 2012-10-11 | Irm Llc | Compositions and methods for modulating lpa receptors |
Also Published As
| Publication number | Publication date |
|---|---|
| US11365185B2 (en) | 2022-06-21 |
| EA202090368A1 (ru) | 2020-06-09 |
| WO2019041340A1 (en) | 2019-03-07 |
| CN111032647B (zh) | 2023-05-02 |
| ES2966827T3 (es) | 2024-04-24 |
| EP3679032B1 (en) | 2023-10-04 |
| US12145924B2 (en) | 2024-11-19 |
| SA520411406B1 (ar) | 2022-08-28 |
| US20200231568A1 (en) | 2020-07-23 |
| IL273000A (en) | 2020-04-30 |
| CA3073983C (en) | 2023-10-17 |
| EA039482B1 (ru) | 2022-02-01 |
| KR20200035440A (ko) | 2020-04-03 |
| BR112020002217A2 (pt) | 2020-07-28 |
| JP2020532550A (ja) | 2020-11-12 |
| CN111032647A (zh) | 2020-04-17 |
| JP6854386B2 (ja) | 2021-04-07 |
| WO2019046239A1 (en) | 2019-03-07 |
| IL273000B1 (en) | 2023-04-01 |
| AU2018323969B2 (en) | 2020-07-16 |
| IL273000B2 (en) | 2023-08-01 |
| MX2020002430A (es) | 2020-07-13 |
| CA3073983A1 (en) | 2019-03-07 |
| US20220281845A1 (en) | 2022-09-08 |
| AU2018323969A1 (en) | 2020-02-20 |
| EP3679032A1 (en) | 2020-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102341064B1 (ko) | 리소포스파티드산 수용체 1 (lpar1) 억제제 화합물 | |
| JP4110324B2 (ja) | 新規インダゾール誘導体 | |
| EP2848610B1 (en) | Inhibitors of kinase activity | |
| JP5715713B2 (ja) | 可溶性グアニル酸シクラーゼ活性化因子 | |
| TWI567067B (zh) | ＴｒＫ抑制化合物 | |
| TW202321201A (zh) | 化合物及其用途 | |
| TW202128644A (zh) | 作為lpa受體拮抗劑之三唑胺基甲酸酯吡啶基磺醯胺及其用途 | |
| US12454530B2 (en) | Amido cyclohexane acid derivatives as LPA receptor inhibitors | |
| JP2019505594A (ja) | がんおよび糖尿病の治療に有用な６−アリール−４−モルホリン−１−イルピリドン化合物 | |
| US20230077268A1 (en) | Indazoles and azaindazoles as lrrk2 inhibitors | |
| TW201132630A (en) | Imidazole derivatives | |
| BR112020002217B1 (pt) | Compostos inibidores do receptor de ácido lisfosfatídico 1 (lpar1) | |
| IL296632A (en) | phd inhibitory compounds, compositions and use | |
| US20200165225A1 (en) | Bace1 inhibitors for treatment of alzheimer's disease | |
| TW202219047A (zh) | 靶向gpr35之治療劑 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 4 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 5 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE) Year of fee payment: 5 |